Summit Trail Advisors LLC Trims Stock Holdings in Danaher Co. (NYSE:DHR)

Summit Trail Advisors LLC cut its holdings in shares of Danaher Co. (NYSE:DHR) by 9.8% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,734 shares of the conglomerate’s stock after selling 946 shares during the quarter. Summit Trail Advisors LLC’s holdings in Danaher were worth $2,023,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Wellington Management Group LLP grew its stake in Danaher by 18.6% during the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock worth $6,185,203,000 after buying an additional 3,905,449 shares during the last quarter. Allen Investment Management LLC grew its position in shares of Danaher by 1,440.7% during the third quarter. Allen Investment Management LLC now owns 1,100,399 shares of the conglomerate’s stock worth $273,009,000 after acquiring an additional 1,028,976 shares during the last quarter. J.P. Morgan Private Wealth Advisors LLC bought a new stake in Danaher in the 3rd quarter valued at about $178,850,000. Alecta Tjanstepension Omsesidigt acquired a new position in Danaher during the 4th quarter valued at about $161,994,000. Finally, Harris Associates L P grew its position in Danaher by 27.7% in the 3rd quarter. Harris Associates L P now owns 2,963,899 shares of the conglomerate’s stock worth $735,343,000 after purchasing an additional 642,759 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Price Performance

Shares of NYSE DHR traded down $0.98 during mid-day trading on Monday, reaching $247.40. The company had a trading volume of 1,593,955 shares, compared to its average volume of 2,755,556. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $259.00. The stock has a market cap of $183.25 billion, a PE ratio of 41.93, a P/E/G ratio of 3.82 and a beta of 0.83. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. The company has a 50-day moving average price of $248.48 and a two-hundred day moving average price of $232.60.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. During the same quarter in the previous year, the company earned $2.36 EPS. The business’s revenue for the quarter was down 2.6% compared to the same quarter last year. On average, equities analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, April 26th. Investors of record on Thursday, March 28th were given a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. The ex-dividend date was Wednesday, March 27th. This is an increase from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio is 18.31%.

Insiders Place Their Bets

In related news, SVP Georgeann Couchara sold 2,622 shares of the company’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the transaction, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at $1,029,891.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP Georgeann Couchara sold 2,622 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the sale, the senior vice president now directly owns 4,244 shares in the company, valued at $1,029,891.48. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Rainer Blair sold 47,175 shares of the business’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the transaction, the chief executive officer now directly owns 115,995 shares in the company, valued at $28,908,273.90. The disclosure for this sale can be found here. In the last three months, insiders have sold 107,273 shares of company stock worth $26,813,819. Corporate insiders own 10.90% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Robert W. Baird boosted their price objective on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. KeyCorp increased their price target on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Royal Bank of Canada lifted their price objective on shares of Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Bank of America raised their target price on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research note on Wednesday, April 24th. Finally, HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and increased their price objective for the company from $250.00 to $280.00 in a report on Wednesday, April 17th. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $267.31.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.